

OVERVIEW – Thursday, 29 September 2011

Room	Plenary	Harvard	Stanford	Princeton	Yale 2	Foyer	
Time							
09.30 – 10.15	Opening Ceremony					Registration Counter Opening Hours: 08.00 – 18.00	
10.15 – 11.00	PL-01 A hundred years of schizophrenia: from Bleuler to DSM-V/ ICD-11						
Coffee Break							
11.30 – 13.00	S-01 Developments in DSM-V and ICD-11 with respect to schizophrenia	S-02 Suicide and suicidal behavior in recent onset psychotic disorders	S-03 Brain imaging in the early stages of schizophrenia	S-04 Advances in animal models of schizophrenia: genes, environment, and prevention to biological foundations			
13.00 – 14.30	Lunch Break 13.30 – 14.30 h ▶ Guided Poster Sessions P-01 to P-03 P-01: Drug treatment I: Clinical P-02: Co-morbidity P-03: Neuroimaging						
14.30 – 16.00	S-05 The future of psychiatric genetics beyond GWAS	S-06 Efficacy and mechanisms of cognitive behavior therapy for psychosis results of the POSITIVE network	S-07 Insight in psychosis: cognitive and neural basis, and implications for treatment	S-08 Neuroprotective strategies in schizophrenia	W-01 MedicaWiki: a webbased independent evidence based psychopharmacological prescription decision system		
Coffee Break							
16.30 – 18.00	S-09 Novel therapeutic targets for treating schizophrenia	S-10 Cognitive behaviour therapy for psychosis: what do we know about its effectiveness and neural correlates?	O-01 Co-morbidity	S-11 Motor symptoms as an intrinsic component of schizophrenia pathobiology			
18.00 – 19.00	Welcome Reception in the Foyer						

Abbreviations

PL – Plenary Lecture	W – Workshop
S – Symposium	O – Oral Presentation

OVERVIEW – Friday, 30 September 2011

Room Time	Plenary	Harvard	Stanford	Princeton	Yale 2	Foyer	
08.30 – 10.00	S-12 Negative symptoms of schizophrenia: assessment, domains and relationships with outcome	S-13 Antipsychotics in the elderly	S-14 Glutamate dysfunction in schizophrenia and bipolar disorder: evidence from genetics and brain imaging	O-02 Epidemiology and clinical phenotypes		Registration Counter Opening Hours: 08.00 – 18.30	
Coffee Break							
10.30 – 12.00	S-15 Cognition in schizophrenia: from neural mechanisms to psychological interventions	S-16 EPA position statements concerning schizophrenia and beyond	S-17 Social cognition and violent behavior in schizophrenia	O-03 Early stages of schizophrenia			
12.15 – 13.00	PL-02 Schizophrenia treatment and prevention – facts and visions						
13.00 – 14.30	Lunch Break 13.30 – 14.30 h ▶ Guided Poster Sessions P-04 to P-07 P-04: Epidemiology, diagnosis P-05: Genetics, neurotransmission P-06: Neurobiology P-07: Drug treatment II: Basic						
14.30 – 16.00	W-02 Past, current and future European schizophrenia research projects	O-04 Drug and other somatic treatments	S-18 Schizophrenia – a mild encephalitis?	S-19 Psychomotor symptoms in schizophrenia	W-03 Writing manuscripts for publication in English language scientific journals		
Coffee Break							
16.30 – 18.00	S-20 Toxicity of relapse	S-21 Co-morbidity of schizophrenia and physical illness	S-22 Advances in understanding the causes of schizophrenia	S-23 PREVENT: a multidimensional study of people at risk to develop first episode psychosis:...	until 17.30 h		
18.15 – 19.45		S-24 Strength based treatment in an early psychosis ACT team: engaging the troublesome avoiders	S-25 Psychotic symptoms in schizophrenia – biological correlates, clinical outcome and therapeutic consequences	O-05 Psychosocial treatment			

OVERVIEW – Saturday, 1 October 2011

Room Time	Plenary	Harvard	Stanford	Princeton	Foyer
08.30 – 10.00	S-26 Psychosis: psychological therapies and their mechanisms of action	S-27 First-episode programmes: concepts and proven evidence	S-28 Dopaminergic and glutamatergic dysfunction in schizophrenia	O-06 Genetics and neurobiology	Registration Counter Opening Hours: 08.00 – 16.00
Coffee Break					
10.30 – 12.00	W-04 European practice guidelines: a need for harmonisation?	S-29 Understanding minds: a conceptual framework in the research and clinical features of schizophrenia	S-30 Early recognition and early intervention: facts and visions	S-31 Animal models of schizophrenia between genotype, endophenotype, nongenetic second hit and the disease	
12.15 – 13.00	PL-03 Social cognition and schizophrenia				
13.00 – 14.30	Lunch Break 13.30 – 14.30 h ► Guided Poster Sessions P-08 to P-11 P-08: Outcome P-09: Neuropsychology I: Basic P-10: Neuropsychology II: Clinical P-11: Psychosocial treatment				
14.30 – 16.00	S-32 Classification of different long-term outcomes of psychosis in schizophrenia spectrum – a need for re-conceptualization	S-33 Molecular linkage between energy metabolism and oligodendrocyte pathology in schizophrenia	S-34 Heterogeneity and functional significance of white matter changes in schizophrenia	O-07 Neuropsychology and neuroimaging	